Expression and function of TLR4-induced B1R bradykinin receptor on cardiac fibroblasts
Author
dc.contributor.author
Muñoz Rodríguez, Claudia Muriel
Author
dc.contributor.author
Fernández, Samuel
Author
dc.contributor.author
Osorio, Jose Miguel
Author
dc.contributor.author
Olivares, Francisco
Author
dc.contributor.author
Anfossi, Renatto
Author
dc.contributor.author
Bolivar, Samir
Author
dc.contributor.author
Humeres, Claudio
Author
dc.contributor.author
Boza Fuentes, Pía
Author
dc.contributor.author
Vivar, Raúl
Author
dc.contributor.author
Pardo Jiménez, Viviana Gladys
Author
dc.contributor.author
Hemmings, Karen E.
Author
dc.contributor.author
Turner, Neil A.
Author
dc.contributor.author
Díaz Araya, Guillermo
Admission date
dc.date.accessioned
2018-11-06T19:54:09Z
Available date
dc.date.available
2018-11-06T19:54:09Z
Publication date
dc.date.issued
2018
Cita de ítem
dc.identifier.citation
Toxicology and Applied Pharmacology 351 (2018) 46–56
es_ES
Identifier
dc.identifier.other
10.1016/j.taap.2018.05.011
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/152428
Abstract
dc.description.abstract
Cardiac fibroblasts (CF) are key cells for maintaining extracellular matrix (ECM) protein homeostasis in the heart, and for cardiac repair through CF-to-cardiac myofibroblast (CMF) differentiation. Additionally, CF play an important role in the inflammatory process after cardiac injury, and they express Toll like receptor 4 (TLR4), B1 and B2 bradykinin receptors (B1R and B2R) which are important in the inflammatory response. B1R and B2R are induced by proinflammatory cytokines and their activation by bradykinin (BK: B2R agonist) or des-arg-kallidin (DAKD: B1R agonist), induces NO and PGI2 production which is key for reducing collagen I levels. However, whether TLR4 activation regulates bradykinin receptor expression remains unknown. CF were isolated from human, neonatal rat and adult mouse heart. B1R mRNA expression was evaluated by qRT-PCR, whereas B1R, collagen, COX-2 and iNOS protein levels were evaluated by Western Blot. NO and PGI2 were evaluated by commercial kits. We report here that in CF, TLR4 activation increased B1R mRNA and protein levels, as well as COX-2 and iNOS levels. B1R mRNA levels were also induced by interleukin-1 alpha via its cognate receptor IL-1R1. In LPS-pretreated CF the DAKD treatment induced higher responses with respect to those observed in non LPS-pretreated CF, increasing PGI2 secretion and NO production; and reducing collagen I protein levels in CF. In conclusion, no significant response to DAKD was observed (due to very low expression of B1R in CF) - but preactivation of TLR4 in CF, conditions that significantly enhanced B1R expression, led to an additional response of DAKD.
es_ES
Patrocinador
dc.description.sponsorship
FONDECYT
1130300
1170425
CONICYT
21120401
FONDAP ACCDiS
15130011
British Heart Foundation
PG/11/80/29135